MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer

MERAIODE: A Phase II Redifferentiation Trial with Trametinib and ¹³¹I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer

Thyroid. 2023 Sep;33(9):1124-1129. doi: 10.1089/thy.2023.0240. Epub 2023 Jul 26.

Sophie Leboulleux^{1

2}, Daniele Benisvy³, David Taieb⁴, Marie Attard⁵, Claire Bournaud⁶, Marie Terroir-Cassou-Mounat^{1

7}, Ludovic Lacroix^{8

9}, Nadege Anizan^{1

10}, Aurelie Schiazza³, Marie Eve Garcia¹¹, Abir Al Ghuzlan⁸, Livia Lamartina¹, Martin Schlumberger¹, Yann Godbert¹², Isabelle Borget¹³

¹ Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and University Paris Saclay, Villejuif, France.
² Department of Endocrinology, Diabetology, Nutrition and Therapeutic Education, Hôpitaux Universitaires de Genève, Geneve, Switzerland.
³ Department of Nuclear Medicine, CLCC Antoine Lacassagne, Nice, France.
⁴ Department of Nuclear Medicine, CHU de La Timone, Marseille, France.
⁵ Department of Imaging Gustave Roussy and University Paris Saclay, Villejuif, France.
⁶ Department of Nuclear Medicine, Hospices Civils de Lyon, Lyon, France.
⁷ Department of Nuclear Medicine UICT Oncopole, CLCC Institut Claudius Regaud, Toulouse, France.
⁸ Department of Medical Biology and Pathology, Gustave Roussy and University Paris Saclay, Villejuif, France.
⁹ AMMICa UAR3655/US23, Gustave Roussy, Villejuif, France.
¹⁰ Department of Physics, Gustave Roussy and University Paris Saclay, Villejuif, France.
¹¹ Department of Oncology, CHU de La Timone, Marseille, France.
¹² Department of Oncology and Department of Nuclear Medicine, CLCC Institut Bergonié, Bordeaux, France.
¹³ Department of Epidemiology and Biostatistics, Gustave Roussy and University Paris Saclay, Villejuif, France.

No abstract available